Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.

This distinction between true value and value traps can challenge even the most skilled investors. Luckily for you, we started StockStory to help you uncover exceptional companies. Keeping that in mind, here is one value stock offering a compelling risk-reward profile and two best left ignored.

Two Value Stocks to Sell:

J. M. Smucker (SJM)

Forward P/E Ratio: 9.8x

Best known for its fruit jams and spreads, J.M Smucker (NYSE: SJM) is a packaged foods company whose products span from peanut butter and coffee to pet food.

Why Do We Steer Clear of SJM?

1. Flat unit sales over the past two years indicate demand is soft and that the company may need to revise its product strategy
2. Efficiency has decreased over the last year as its operating margin fell by 11.4 percentage points
3. Underwhelming 0.8% return on capital reflects management’s difficulties in finding profitable growth opportunities, and its falling returns suggest its earlier profit pools are drying up

J. M. Smucker is trading at $98.35 per share, or 9.8x forward P/E. If you’re considering SJM for your portfolio, see our FREE research report to learn more.

GoodRx (GDRX)

Forward P/E Ratio: 6.3x

Started in 2011 to tackle the problem of high prescription drug costs in America, GoodRx (NASDAQ: GDRX) operates a digital platform that helps consumers find lower prices on prescription medications through price comparison tools and discount codes.

Why Should You Sell GDRX?

1. 2.4% annual revenue growth over the last two years was slower than its healthcare peers
2. Subscale operations are evident in its revenue base of $796.9 million, meaning it has fewer distribution channels than its larger rivals
3. Push for growth has led to negative returns on capital, signaling value destruction

GoodRx’s stock price of $2.08 implies a valuation ratio of 6.3x forward P/E. Check out our free in-depth research report to learn more about why GDRX doesn’t pass our bar.

One Value Stock to Buy:

Evercore (EVR)

Forward P/E Ratio: 14.9x

Founded in 1995 as a boutique advisory firm focused on independence and client trust, Evercore (NYSE: EVR) is an independent investment banking firm that provides strategic advisory, capital markets, and wealth management services to corporations, financial sponsors, and high-net-worth individuals.

Why Is EVR a Top Pick?

1. Annual revenue growth of 25.9% over the last two years was superb and indicates its market share increased during this cycle
2. Incremental sales over the last two years have been highly profitable as its earnings per share increased by 50.2% annually, topping its revenue gains
3. Market-beating return on equity illustrates that management has a knack for investing in profitable ventures

At $280.95 per share, Evercore trades at 14.9x forward P/E. Is now the time to initiate a position? See for yourself in our full research report, it’s free.

Stocks We Like Even More

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.